Topic: Tics Disorder

Disclaimer: This information is intended for educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Clinicians must exercise their independent medical judgment and consider individual patient circumstances when making healthcare decisions. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to patient care.

---

Tics Disorder

Overview

• Definition: Tic disorders are neurodevelopmental conditions characterized by sudden, rapid, recurrent, nonrhythmic motor movements or vocalizations called tics. Tics are typically suppressible for periods but result in an uncomfortable inner tension (premonitory urge) if suppressed.
  • Motor Tics: Involve muscle movements (e.g., eye blinking, head jerking, shoulder shrugging).
  • Vocal Tics: Involve sounds produced by air movement through the nose, mouth, or throat (e.g., sniffing, throat clearing, grunting, complex vocalizations like words or phrases).
  • Simple Tics: Brief, single muscle group (e.g., eye blink, sniff, grunt).
  • Complex Tics: Coordinated movements involving multiple muscle groups or recognizable words/phrases (e.g., head turn with shoulder shrug, repeating words, echolalia, coprolalia).
• Epidemiology:
  • Prevalence:
    • Provisional Tic Disorder: Up to 10-20% of school-aged children experience transient tics.
    • Persistent (Chronic) Motor or Vocal Tic Disorder: Approximately 0.5-3% of school-aged children.
    • Tourette's Disorder (TD): Estimated prevalence ranges from 0.3-0.8% in children and adolescents, though some studies suggest higher rates (up to 1%).
  • Demographics:
    • Age of Onset: Typically between ages 5 and 7 years, rarely before age 2 or after age 18.
    • Gender: Males are affected 3-4 times more frequently than females for TD and chronic tic disorders.
    • Geographic/Ethnic: Occurs across all cultures and ethnic groups.
• Classification (DSM-5 Criteria):
  • Tourette's Disorder (TD):
    • Both multiple motor tics and one or more vocal tics have been present at some time during the illness, though not necessarily concurrently.
    • Tics may wax and wane in frequency but have persisted for more than 1 year since first tic onset.
    • Onset before age 18 years.
    • The disturbance is not attributable to the physiological effects of a substance (e.g., cocaine) or another medical condition (e.g., Huntington's disease, postviral encephalitis).
  • Persistent (Chronic) Motor or Vocal Tic Disorder:
    • Either multiple motor tics or one or more vocal tics have been present, but not both.
    • Tics may wax and wane in frequency but have persisted for more than 1 year since first tic onset.
    • Onset before age 18 years.
    • The disturbance is not attributable to the physiological effects of a substance or another medical condition.
    • Criteria have never been met for Tourette's Disorder.
  • Provisional Tic Disorder:
    • Single or multiple motor and/or vocal tics.
    • Tics have been present for less than 1 year since first tic onset.
    • Onset before age 18 years.
    • The disturbance is not attributable to the physiological effects of a substance or another medical condition.
    • Criteria have never been met for Tourette's Disorder or Persistent (Chronic) Motor or Vocal Tic Disorder.
  • Other Specified/Unspecified Tic Disorder: Used when criteria are met for a tic disorder but do not fit into the above categories (e.g., tic-like movements due to medical condition, substance-induced tics, tic disorder with onset ≥18 years).

Pathophysiology

• Mechanism: Tic disorders are complex neurodevelopmental conditions with a strong genetic component and involve dysfunction in specific brain circuits.
  • Cortico-Striato-Thalamo-Cortical (CSTC) Circuits: Leading theory suggests dysregulation within these basal ganglia-thalamo-cortical loops, particularly involving the striatum (caudate, putamen). These circuits are involved in habit formation, motor control, and reward processing.
  • Dopaminergic System: Evidence points to abnormal dopamine neurotransmission. Hypersensitivity or dysfunction of postsynaptic D2 dopamine receptors in the striatum is a prominent hypothesis, explaining the efficacy of dopamine receptor blocking agents.
  • Other Neurotransmitters: Dysregulation of other neurotransmitter systems, including norepinephrine, serotonin, GABA, and glutamate, may also play a role, contributing to the high comorbidity with conditions like OCD and ADHD.
  • Neuroanatomy: Structural and functional neuroimaging studies suggest differences in brain regions such as the basal ganglia (putamen, globus pallidus), anterior cingulate cortex, and prefrontal cortex in individuals with tic disorders.
  • Genetic Factors: Highly heritable. Twin studies show high concordance rates. Multiple genes are likely involved, with a complex polygenic inheritance pattern rather than a single gene defect. Genes related to neurodevelopment, synaptic function, and neurotransmitter systems are under investigation (e.g., SLITRK1, HDC, IMMP2L).
  • Neurodevelopmental Factors: Tics are considered neurodevelopmental, emerging during childhood and often changing over time. Abnormalities in brain development and connectivity appear to be crucial.
• Risk Factors:
  • Genetic Predisposition: Strongest risk factor. Family history of tics, Tourette's Disorder, OCD, or ADHD significantly increases risk.
  • Male Sex: Males are more commonly affected.
  • Prenatal/Perinatal Factors: Maternal stress during pregnancy, severe nausea during pregnancy, complications during delivery (e.g., pre-eclampsia, premature birth, low birth weight, maternal smoking).
  • Comorbid Psychiatric Conditions: Strong association with ADHD and OCD, which often precede tic onset or co-occur.
  • Environmental Triggers: Stress, fatigue, excitement, illness can exacerbate existing tics, but do not cause primary tic disorders.
  • PANDAS/PANS: In a subset of individuals, sudden onset or exacerbation of tics may be associated with Group A Streptococcal infection (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections - PANDAS) or other infections/inflammatory triggers (Pediatric Acute-onset Neuropsychiatric Syndrome - PANS). This remains an area of ongoing research and clinical debate regarding diagnostic criteria and prevalence.
• Protective Factors: Not well-established for primary prevention. However, factors that may mitigate severity or impact include:
  • Early diagnosis and psychoeducation.
  • Supportive family and school environment.
  • Effective management of comorbid conditions (e.g., ADHD, OCD).
  • Learning and utilizing behavioral strategies (e.g., Habit Reversal Training).

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Tics: Involuntary, sudden, rapid, recurrent, nonrhythmic movements or vocalizations.
  • Premonitory Urges: An uncomfortable, often localized, sensation preceding a tic (e.g., itch, tension, tingling, burning). The tic provides a temporary sense of relief. Often described in older children and adults.
  • Suppressibility: Tics can be voluntarily suppressed for periods, but this often leads to an increase in internal tension and a subsequent "burst" of tics.
  • Waxing and Waning Course: Tics fluctuate in frequency, intensity, and type over time. They can change locations, appear, disappear, and reappear.
  • Exacerbating Factors: Stress, anxiety, fatigue, excitement, illness.
  • Alleviating Factors: Focused attention on an engaging task, relaxation.
• Early Signs:
  • Typically begin in early childhood (5-7 years old).
  • Often start as simple motor tics, frequently involving the face and head (e.g., eye blinking, nose twitching, head jerking, shoulder shrugging).
  • Vocal tics may follow motor tics or appear later.
  • Initial tics are often transient and may be misidentified as habits or allergies.
• Advanced Signs:
  • Progression to multiple motor tics and one or more vocal tics (meeting Tourette's criteria).
  • Increased complexity of tics (e.g., jumping, touching, bending, repeating words/phrases, coprolalia, echolalia).
  • Higher frequency and intensity of tics.
  • Significant functional impairment in social, academic, or occupational settings.
  • Emergence of self-injurious tics (e.g., head banging, punching self).
• Atypical Presentations:
  • Sudden, explosive onset of severe, complex tics, sometimes raising suspicion for PANDAS/PANS (requires specific diagnostic criteria).
  • Tics worsening dramatically with minimal fluctuation, or presenting with atypical movements (e.g., dystonic postures) that mimic other movement disorders.
  • Late onset (after age 18): Requires careful evaluation for secondary causes (e.g., drug-induced, neurological conditions).
  • Pure Obsessional Tics: Some tics can be difficult to distinguish from compulsions, especially "sensory tics" where the urge to tic is central.

Physical Examination

• Inspection: The cornerstone of physical examination for tic disorders.
  • Observation: Directly observe for presence, type (motor/vocal, simple/complex), frequency, intensity, duration, and anatomical distribution of tics. This may require extended observation, as tics can be suppressed in a clinical setting.
  • Provocation: Ask the patient to attempt to suppress tics, noting the difficulty and subsequent rebound.
  • Context: Note if tics are exacerbated by stress or focused attention.
  • Self-Injurious Tics: Look for signs of injury (e.g., bruises, skin lesions).
• Palpation: Generally not relevant for tic diagnosis itself, but may be used to rule out musculoskeletal causes of abnormal movements or to assess for tenderness in areas affected by severe motor tics (e.g., neck pain from head jerking).
• Special Tests: No specific diagnostic tests for primary tic disorders.
  • Neurological Examination: Essential to rule out other neurological conditions that can mimic tics (e.g., dystonia, chorea, myoclonus, stereotypies, seizures). A normal general neurological exam supports a primary tic disorder diagnosis.
  • Developmental Assessment: For children, assess for developmental delays or learning disabilities often co-occurring.
  • Mental Status Examination: To screen for common comorbidities like ADHD, OCD, anxiety, depression.

Diagnostic Approach

History Taking

• Key Questions:
  • Tic Characteristics:
    • "What do you notice your child/you doing?" "What sounds do you hear?"
    • "When did the tics start?" (Age of onset is crucial).
    • "How long have they been present?" (Duration >1 year for chronic tic disorders/TD, <1 year for provisional).
    • "Have they changed over time? Are they always the same or do they vary?" (Waxing/waning course).
    • "Are they constant, or do they come and go?"
    • "Can you stop them? What happens if you try to stop them?" (Suppressibility, premonitory urges).
    • "Do you feel an urge before a tic?" "What does it feel like?"
    • "What makes them better or worse?" (Stress, fatigue, excitement, relaxation).
    • "How much do the tics bother you or interfere with your daily life?" (Impact on function).
  • Associated Symptoms: "Do you have problems with attention, focusing, or hyperactivity?" (ADHD). "Do you have repetitive thoughts or actions, or feel you need to do things 'just right'?" (OCD). "Do you feel anxious or sad often?" (Anxiety/Depression).
  • Family History: "Does anyone else in the family have tics, Tourette's, ADHD, or OCD?" (Genetic predisposition).
  • Medical History: Birth history, developmental milestones, head injuries, past infections (especially Group A Strep), current medications, substance use.
  • Exclusion: Rule out secondary causes: medication side effects (stimulants, antiepileptics), drug use (cocaine, amphetamines), genetic disorders (e.g., Huntington's), post-infectious (e.g., encephalitis), autoimmune conditions.
• Red Flags:
  • Sudden, acute onset of severe, complex tics or other neuropsychiatric symptoms (e.g., OCD, emotional lability) in a child, especially if preceded by infection (consider PANDAS/PANS).
  • Onset after age 18: Requires thorough investigation for secondary causes (substance-induced, neurological disease, medication side effects).
  • Fixed neurological deficits (e.g., weakness, sensory loss, abnormal reflexes) accompanying movements.
  • Associated systemic symptoms (e.g., fever, rash, weight loss).
  • Movements that are truly involuntary and non-suppressible, or appear during sleep, suggesting other movement disorders or seizures.
  • Rapidly progressive symptoms or cognitive decline.

Laboratory Tests

• First-Line: No routine laboratory tests are recommended for the diagnosis of primary tic disorders. Diagnosis is purely clinical.
• Confirmatory: Not applicable for primary tic disorders.
• Monitoring:
  • If using medications:
    • Alpha-2 agonists (Clonidine, Guanfacine): Baseline ECG (especially if cardiac history or other risk factors), blood pressure, heart rate monitoring.
    • Antipsychotics (Aripiprazole, Risperidone, Haloperidol, Pimozide): Baseline and periodic monitoring of metabolic parameters (weight, BMI, fasting glucose, HbA1c, lipid panel), LFTs. ECG if QTc prolongation risk (Pimozide, Haloperidol).
  • PANDAS/PANS workup (if suspected based on acute onset and specific criteria):
    • Antistreptolysin O (ASO) and anti-DNase B titers (if recent strep infection suspected).
    • Other autoimmune/inflammatory markers may be considered but are not specific for PANS (e.g., ESR, CRP, antineuronal antibodies, though their clinical utility is debated). Caution: Serologic evidence of strep infection alone does not diagnose PANDAS/PANS, and this diagnosis should be made cautiously by experienced clinicians.

Imaging

• Recommended: Not routinely recommended for the diagnosis of primary tic disorders.
• Advanced: Brain MRI or CT scan may be considered in cases with:
  • Atypical presentation: Late onset (>18 years), sudden onset, rapidly progressive symptoms.
  • Focal neurological signs on examination.
  • Head trauma preceding tic onset.
  • Suspicion of other neurological conditions (e.g., structural lesions, demyelinating disease, vascular malformations, metabolic disorders).

Management

Acute Management

Acute management for tic disorders is generally not required unless tics are causing immediate danger or severe distress. - Immediate: * Safety: If tics are self-injurious (e.g., head banging, severe punching), immediate steps to ensure safety (e.g., padding, helmets, 1:1 supervision) are paramount. * Crisis Management: For acute, severe exacerbations leading to significant functional impairment or severe distress, a brief course of rapidly acting medication (e.g., benzodiazepine for acute anxiety, or low-dose antipsychotic) may be considered in a supervised setting (e.g., inpatient or day program), but this is rare. - Stabilization: * Environmental Modification: Reducing stress, providing a calm environment. * Psychoeducation: Reassure patient and family, explain the waxing/waning nature of tics, and that they are not voluntary. * Referral: For acute severe cases, immediate referral to a child neurologist or psychiatrist experienced in movement disorders. - Emergency: * Rarely, severe self-injurious tics (SITs) may necessitate emergency department visits for injury management or psychiatric evaluation for inpatient admission to ensure safety and stabilize symptoms.

Chronic Management

Management is individualized based on tic severity, functional impairment, presence of premonitory urges, and comorbidities. The goal is to reduce tic-related distress and improve quality of life, not necessarily to eliminate all tics.

Non-pharmacological (First-Line for mild-moderate impairment):

• Psychoeducation: Essential for patient and family. Understanding the nature of tics, their waxing/waning course, and the role of premonitory urges helps reduce anxiety and improve coping.
• Supportive Therapy: Providing a supportive environment at home and school. Addressing bullying or social stigma.
• Comprehensive Behavioral Intervention for Tics (CBIT): Evidence-based psychotherapy, considered first-line for impairing tics.
  • Habit Reversal Training (HRT): Core component of CBIT. Teaches awareness of premonitory urges and tics, and then trains patients to engage in a "competing response" that is physically incompatible with the tic, held until the urge subsides.
  • Function-Based Interventions: Modifying environmental factors that exacerbate tics.
  • Relaxation Training: Techniques (e.g., deep breathing, progressive muscle relaxation) to manage anxiety and stress that can worsen tics.
• Psychotherapy: For associated conditions (e.g., CBT for OCD or anxiety, social skills training).
• School Accommodations: Educating school staff, allowing breaks, alternative testing environments, or reduced workload during periods of tic exacerbation.

Pharmacological (For moderate-severe impairment or when behavioral therapy is insufficient):

Medication choice depends on tic severity, specific tic types, side-effect profile, and comorbidities. Start low, go slow.

1. Alpha-2 Adrenergic Agonists (First-line pharmacological): Often preferred due to generally milder side effects and efficacy for tics and sometimes ADHD symptoms.

   • Guanfacine Extended-Release (Intuniv):
     • Dosing: Start at 0.5-1 mg/day, titrate slowly by 0.5-1 mg weekly to a typical dose of 1-4 mg/day (max 4 mg/day). Can be given once daily.
     • Side Effects: Sedation, fatigue, hypotension, bradycardia.
   • Clonidine (Kapvay - ER, Catapres - IR):
     • Dosing: Start at 0.025-0.05 mg/day, titrate slowly to 0.1-0.3 mg/day (max 0.6 mg/day) in divided doses (IR) or once daily (ER).
     • Side Effects: Sedation, fatigue, dry mouth, hypotension, bradycardia.
     • Note: Discontinue gradually to avoid rebound hypertension.

2. Dopamine Receptor Blockers (Antipsychotics) (Second-line pharmacological): More effective for tic suppression but with a higher risk of side effects. Atypical antipsychotics are generally preferred over typical antipsychotics due to a lower risk of extrapyramidal symptoms (EPS) and tardive dyskinesia.

   • Atypical Antipsychotics:

     • Aripiprazole (Abilify):
       • Dosing: Start at 2 mg/day, titrate slowly to 5-15 mg/day (max 30 mg/day).
       • Side Effects: Akathisia, sedation/insomnia, weight gain, metabolic changes (less than other atypicals), EPS (dose-dependent).
     • Risperidone (Risperdal):
       • Dosing: Start at 0.25-0.5 mg/day, titrate slowly to 0.5-4 mg/day (max 6 mg/day).
       • Side Effects: Sedation, weight gain, metabolic changes, prolactin elevation, EPS.
     • Pimozide (Orap):
       • Dosing: Start 0.5-1 mg/day, titrate slowly by 0.5 mg every 5-7 days to 2-10 mg/day (max 10 mg/day for tics).
       • Side Effects: QTc prolongation (requires baseline and periodic ECGs), EPS (akathisia, dystonia, parkinsonism, tardive dyskinesia), sedation, depression, weight gain. Reserved for severe, refractory tics due to cardiac risk and EPS.

   • Typical Antipsychotics:

     • Haloperidol (Haldol):
       • Dosing: Start 0.25-0.5 mg/day, titrate slowly to 1-5 mg/day (max 10 mg/day).
       • Side Effects: High risk of EPS, tardive dyskinesia, sedation, QTc prolongation. Generally reserved for severe, refractory tics.

3. Other Pharmacological Agents:

   • Topiramate (Topamax): May reduce tics in some patients, potentially helpful if comorbid migraine or seizure disorder.
     • Dosing: Start 25 mg/day, titrate to 50-200 mg/day.
     • Side Effects: Cognitive dulling, paresthesias, weight loss, kidney stones.
   • Botulinum Toxin Injections: For severe, focal motor or vocal tics (e.g., disabling neck tics, vocal tics affecting specific muscles). Injected directly into the affected muscle. Effects last 3-4 months.
   • Benzodiazepines: Rarely used for acute, severe tic exacerbations due to risk of dependence. Not for chronic management.

Monitoring (Long-term follow-up)

• Tic Severity: Regular assessment using standardized scales (e.g., Yale Global Tic Severity Scale - YGTSS) or clinical global impression scales.
• Medication Side Effects: Monitor for specific side effects of prescribed medications (see above).
• Functional Impact: Assess academic performance, social interactions, emotional well-being.
• Comorbidities: Continuously screen for and manage ADHD, OCD, anxiety, depression, and other associated conditions.
• Growth and Development: For children, monitor physical growth, pubertal development, and overall neurodevelopmental progress.

Treatment Algorithms

• First-Line:
  1. Diagnosis and Psychoeducation: Provide comprehensive information to patient and family. Reassurance and support.
  2. Environmental Modifications: Identify and reduce tic triggers (stress, fatigue).
  3. Behavioral Therapy: If tics are functionally impairing or cause distress, start with Comprehensive Behavioral Intervention for Tics (CBIT), including Habit Reversal Training (HRT).
• Second-Line:
  1. If behavioral therapy alone is insufficient or tics remain significantly impairing, consider adding Pharmacological Treatment.
  2. Alpha-2 Adrenergic Agonists: Start with guanfacine ER or clonidine.
• Third-Line (or if Alpha-2 Agonists are ineffective/not tolerated):
  1. Atypical Antipsychotics: Consider aripiprazole or risperidone.
  2. Carefully weigh efficacy vs. side effect profile, especially metabolic and EPS risks.
• Refractory Cases:
  1. Optimize Antipsychotic Regimen: Titrate to higher doses (within recommended limits), or try a different atypical antipsychotic.
  2. Typical Antipsychotics: Consider haloperidol or pimozide, with careful monitoring for serious side effects (e.g., QTc prolongation, tardive dyskinesia).
  3. Adjunctive Therapies: Consider topiramate, or botulinum toxin for specific, focal tics.
  4. Deep Brain Stimulation (DBS): Reserved for severely debilitating, medication-refractory Tourette's Disorder in adults. Involves surgical implantation of electrodes into specific brain regions (e.g., centromedian-parafascicular nucleus of thalamus, globus pallidus internus). Highly selective criteria, specialized centers only.

Complications

• Common:
  • Psychosocial Impact: Social embarrassment, stigmatization, bullying, low self-esteem, social isolation.
  • Academic/Occupational Difficulties: Distraction, difficulty concentrating, inability to complete tasks.
  • Psychiatric Comorbidities: ADHD (most common, ~60%), OCD (~30-50%), anxiety disorders (~20-50%), depression (~15-20%), learning disabilities, sleep disturbances. These often cause more impairment than the tics themselves.
  • Physical Discomfort: Muscle strain, soreness, headaches, eye irritation from repetitive tics.
• Serious:
  • Self-Injurious Tics (SITs): Head banging, punching, eye gouging, biting. Can lead to significant physical harm.
  • Severe Functional Impairment: Inability to attend school, hold a job, or maintain relationships due to tic severity or comorbid conditions.
  • Medication Side Effects: Metabolic syndrome, tardive dyskinesia, QTc prolongation, severe sedation, dystonic reactions.
• Long-term:
  • Persistence of tics into adulthood (around 10-20% of TD cases).
  • Chronic mental health issues related to comorbidities and living with a chronic condition.
  • Potential for cognitive and social development delays if not adequately managed.

Prognosis

• Factors:
  • Severity and Type of Tics: Generally, severe complex tics, especially those with self-injurious components, predict a poorer prognosis.
  • Comorbidity Burden: The presence and severity of comorbid ADHD, OCD, anxiety, and depression are the strongest predictors of long-term functional impairment and poorer quality of life, often more so than the tics themselves.
  • Age of Onset: Early onset (before age 8) may be associated with a more persistent course.
  • Family History/Support: A supportive family environment and access to effective treatment can improve outcomes.
  • Early Intervention: Prompt diagnosis and behavioral/pharmacological intervention can mitigate severity and complications.
• Survival: Tic disorders do not directly affect life expectancy.
• Quality of Life: Can be significantly impaired, especially during peak tic severity (late childhood to early adolescence) and if comorbidities are untreated. Many individuals (up to 80%) experience significant improvement in tic severity in late adolescence or early adulthood, with some achieving tic remission. However, comorbidities often persist.

Prevention

• Primary: Currently, there are no established primary prevention strategies for tic disorders given their strong genetic and neurodevelopmental basis.
  • Genetic counseling may be considered for families with a strong history of tic disorders, but genetic factors are complex.
  • Research into prenatal risk factors may one day inform preventative strategies.
• Secondary: Focuses on early detection and intervention to minimize the impact and progression of the disorder.
  • Early Diagnosis: Prompt recognition of tics and accurate diagnosis.
  • Psychoeducation: Educating families and school personnel about tic disorders to reduce stigma and provide support.
  • Behavioral Interventions: Early access to CBIT/HRT can help manage tics and teach coping skills, potentially preventing escalation or chronic impairment.
  • Comorbidity Screening: Regular screening for and early management of ADHD, OCD, anxiety, and depression to reduce overall burden and improve outcomes.
• Tertiary: Aimed at preventing complications and optimizing long-term outcomes for individuals already diagnosed.
  • Ongoing Management: Adherence to treatment plans (behavioral therapy, medication).
  • Support Services: Providing access to psychological support, school accommodations, and vocational guidance.
  • Comorbidity Management: Vigilant and ongoing treatment of associated psychiatric conditions.
  • Promoting Resilience: Encouraging self-advocacy, self-management, and engagement in supportive communities.

Special Populations

• Pediatric:
  • Diagnosis: Most common population. Emphasize clinical diagnosis based on DSM-5 criteria. Rule out other childhood movement disorders.
  • Treatment: Psychoeducation and CBIT are first-line. Medications (alpha-2 agonists first, then atypical antipsychotics) are reserved for functionally impairing tics. Careful consideration of medication side effects on developing brain and body.
  • Comorbidities: High rates of ADHD and OCD. Address these aggressively, as they often cause more impairment.
• Geriatric:
  • Onset: Very rare for primary tic disorders to begin in old age. New onset tics require thorough workup for secondary causes (e.g., neurodegenerative diseases, medication side effects, cerebrovascular disease, infections).
  • Management: If tics persist from childhood, medication management needs careful consideration of polypharmacy, comorbidities, and age-related changes in drug metabolism/sensitivity. Lower doses of medications may be necessary.
• Pregnancy:
  • General Approach: Weigh risks vs. benefits of medication. Non-pharmacological interventions are preferred if possible.
  • Medication:
    • Alpha-2 agonists: Limited data, but clonidine/guanfacine generally considered lower risk than antipsychotics.
    • Antipsychotics: Avoid during pregnancy if possible. If necessary, atypical antipsychotics (e.g., aripiprazole, risperidone) have less data for teratogenicity than older typical antipsychotics, but still carry risks. Consult with a high-risk obstetrician or perinatal psychiatrist.
    • Breastfeeding: Medications can pass into breast milk; carefully consider risks to the infant.
• Comorbidities:
  • ADHD: Often treated first, as it frequently causes more impairment. Stimulants can sometimes worsen tics in a minority of patients, but are generally safe and effective. If stimulants exacerbate tics, alpha-2 agonists can address both tics and ADHD symptoms.
  • OCD: Can be highly impairing. Treat with SSRIs (e.g., fluoxetine, sertraline) and/or CBT with exposure and response prevention (ERP). Antipsychotics, particularly aripiprazole, can augment SSRIs for refractory OCD.
  • Anxiety/Depression: Treated with psychotherapy (CBT), SSRIs, or other appropriate medications.
  • Learning Disabilities: Requires comprehensive neuropsychological assessment and individualized educational plans.

Clinical Pearls

• Diagnostic:
  • "Tics are like hiccups for the brain": A useful analogy to explain the involuntary, suppressible, but ultimately irresistible nature of tics to patients and families.
  • Premonitory urges are key: Ask about these sensations. Their presence strongly supports a tic disorder diagnosis, especially in older children and adults.
  • Always observe, don't just ask: Tics can be suppressed in the clinic. Observe the patient during the history, during play (for children), and ask parents/caregivers for videos.
  • Comorbidities are the rule, not the exception: Always screen for and address ADHD, OCD, anxiety, and depression. These often cause more distress and impairment than the tics themselves.
  • Distinguish from other movement disorders: Pay attention to rhythmicity, distractibility, suppressibility. Tics are typically nonrhythmic, distractible, and temporarily suppressible.
• Treatment:
  • "Treat the most impairing symptom first": Often, this is a comorbidity like ADHD or OCD, rather than the tics themselves.
  • Behavioral therapy (CBIT) is first-line: Strongly consider referral, as it is effective with no side effects.
  • Start low, go slow with medication: Especially with alpha-2 agonists and antipsychotics. Titrate slowly to minimize side effects.
  • Set realistic expectations: The goal is tic reduction and functional improvement, not tic elimination. Tics will wax and wane.
  • Educate about medication side effects: Forewarn patients/families about common side effects to improve adherence and reduce anxiety.
• Pitfalls:
  • Over-reliance on medication: Without addressing behavioral strategies and comorbidities, medication alone may be insufficient.
  • Mistaking tics for voluntary habits or attention-seeking: This can lead to frustration, punishment, and increased stress for the patient.
  • Missing comorbidities: Failing to diagnose and treat co-occurring conditions can significantly worsen prognosis and quality of life.
  • Ignoring premonitory urges: These are critical for understanding the patient's experience and for effective behavioral therapy.
  • Discontinuing medications abruptly: Especially alpha-2 agonists, which can cause rebound hypertension, or antipsychotics, which can cause withdrawal dyskinesia.

Recent Updates

• Guidelines: Recent guidelines emphasize the role of CBIT as a first-line intervention for tic disorders, prior to or in conjunction with pharmacotherapy, given its strong evidence base.
• Evidence:
  • Growing evidence supporting the efficacy of atypical antipsychotics like aripiprazole with a favorable side effect profile for tic reduction.
  • Continued research into the genetic underpinnings of Tourette's, with ongoing identification of candidate genes and gene networks, moving towards more targeted therapies in the future.
  • Increased understanding of the neurobiological basis of premonitory urges, supporting their role in the phenomenology of tics.
• Controversies:
  • PANDAS/PANS: The precise diagnostic criteria, prevalence, and optimal treatment strategies for PANDAS/PANS remain controversial. While infections can trigger exacerbations, a direct autoimmune causality in all cases of acute tic onset is debated. Clinicians should exercise caution and follow established criteria.
  • Deep Brain Stimulation (DBS): While effective for severe, refractory cases, optimal target selection (e.g., GPi vs. CM-Pf thalamus) and patient selection criteria continue to be refined.

Key References

• Guidelines:
  • American Academy of Child and Adolescent Psychiatry (AACAP) Practice Parameter for the Assessment and Treatment of Children and Adolescents With Tic Disorders: Provides evidence-based recommendations for diagnosis and management.
  • European Society for the Study of Tourette Syndrome (ESSTS) Guidelines: Comprehensive guidelines for the pharmacological and non-pharmacological treatment of Tourette's Syndrome and other chronic tic disorders.
  • Tourette Association of America (TAA) Professional Guidelines: Regularly updated resources and recommendations for clinicians.
• Studies:
  • The Tourette Syndrome Study Group. A double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. Pediatrics (2014): Landmark study supporting aripiprazole's efficacy.
  • Piacentini J, Woods DW, Scahill L, et al. Behavior Therapy for Children With Tourette Disorder: A Randomized Controlled Trial. JAMA (2010): Key study demonstrating the efficacy of CBIT.
  • Leckman JF, Bloch MH, Smith T, et al. The Yale Global Tic Severity Scale: initial psychometric data.: J Am Acad Child Adolesc Psychiatry (1998): Standardized tic assessment scale.
• Reviews:
  • Robertson MM. Tourette Syndrome, associated conditions and the complexities of treatment. Brain (2000): Classic review of clinical presentation and management.
  • Hirschtritt ME, et al. Phenotypic spectrum and genetic architecture of Tourette syndrome: a new paradigm. Neuron (2015): Comprehensive review on epidemiology, genetics, and clinical features.
  • Walkup JT, et al. Tic disorders: a comprehensive review. Pediatrics in Review (2016): Excellent overview for pediatric practitioners.